NEW YORK (GenomeWeb News) – CombiMatrix said today that its chromosomal microarray test for miscarriage analysis has received conditional approval from the New York State's Department of Health, allowing the company to begin testing patient samples from the state.

"Gaining the conditional license and ultimately the final approval to market and sell our [Product of Conception] test throughout New York is an important milestone for us that will allow us to broaden the market for our number one growth product," CEO Mark McDonough said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.